Payment overview · 2025
General Payments
$702.97
42 reported records · 8 companies
Healthcare provider profile · identity verified
Hung-Jie Jeng
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Adult Health · SAN GABRIEL, CA · NPI 1518367887
Verified facts
What the public records show
CMS Open Payments records show Hung-Jie Jeng received $702.97 in general payments during 2025 across 42 reported records.
AstraZeneca Pharmaceuticals LP accounted for 40.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 13 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Creon, Farxiga, Jardiance, Linzess, Voquezna.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 73 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 68 claims for Linzess by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 102 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 140 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 119 claims for Jardiance by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Entresto by this doctor in 2024.
Phathom Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VOQUEZNA as an associated drug or biological on 90302 records involving 33442 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Voquezna by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $285.57 | 40.6% | 10 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $236.23 | 33.6% | 24 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $51.97 | 7.4% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $41.18 | 5.9% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $28.06 | 4.0% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $23.73 | 3.4% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $19.79 | 2.8% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $16.44 | 2.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $702.97 | 42 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $266.36 | 9 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $232.24 | 23 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $232.24 | 23 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $86.45 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $51.97 | 2 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $41.18 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $28.06 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $23.73 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $19.79 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $19.21 | 1 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $18.51 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $16.44 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $3.99 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CREON creon |
2025 | Creon | 2024 | 73 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 140 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 119 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 68 | exact normalized | Medicare Part D |
| VOQUEZNA voquezna |
2025 | Voquezna | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
73 | 23 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
68 | 18 |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
102 | 67 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
140 | 33 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
119 | 26 |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Phathom Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | VOQUEZNA open payments reported associated product |
CMS Open Payments — General Payments 90302 supporting records · 33442 recipient NPIs · example record 1219216983 |
Voquezna · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 789 | 233 |
| Amlodipine Besylate | Amlodipine Besylate | 690 | 185 |
| Losartan Potassium | Losartan Potassium | 690 | 177 |
| Metformin Hcl | Metformin Hcl | 509 | 127 |
| Omeprazole | Omeprazole | 497 | 188 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 382 | 152 |
| Vascepa | Icosapent Ethyl | 362 | 78 |
| Amoxicillin | Amoxicillin | 296 | 176 |
| Tamsulosin Hcl | Tamsulosin Hcl | 256 | 58 |
| Pravastatin Sodium | Pravastatin Sodium | 249 | 56 |
| Azithromycin | Azithromycin | 247 | 148 |
| Ibuprofen | Ibuprofen | 238 | 141 |
| Allopurinol | Allopurinol | 233 | 60 |
| Icosapent Ethyl | Icosapent Ethyl | 218 | 69 |
| Zolpidem Tartrate | Zolpidem Tartrate | 218 | 83 |
| Ezetimibe | Ezetimibe | 216 | 62 |
| Atenolol | Atenolol | 215 | 51 |
| Clopidogrel | Clopidogrel Bisulfate | 200 | 45 |
| Celecoxib | Celecoxib | 192 | 49 |
| Clonidine Hcl | Clonidine Hcl | 184 | 50 |
| Meloxicam | Meloxicam | 179 | 74 |
| Metoprolol Succinate | Metoprolol Succinate | 176 | 45 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 168 | 46 |
| Azelastine Hcl | Azelastine Hcl | 164 | 58 |
| Diclofenac Sodium | Diclofenac Sodium | 153 | 63 |
| Montelukast Sodium | Montelukast Sodium | 153 | 46 |
| Gabapentin | Gabapentin | 152 | 52 |
| Memantine Hcl | Memantine Hcl | 147 | 36 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 142 | 34 |
| Lidocaine | Lidocaine | 142 | 38 |
| Farxiga | Dapagliflozin Propanediol | 140 | 33 |
| Alendronate Sodium | Alendronate Sodium | 134 | 43 |
| Fluticasone Propionate | Fluticasone Propionate | 133 | 55 |
| Donepezil Hcl | Donepezil Hcl | 123 | 29 |
| Glimepiride | Glimepiride | 121 | 32 |
| Pantoprazole Sodium | Pantoprazole Sodium | 120 | 35 |
| Cyclosporine | Cyclosporine | 119 | 46 |
| Jardiance | Empagliflozin | 119 | 26 |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 105 | 29 |
| Prolia | Denosumab | 102 | 67 |
| Acarbose | Acarbose | 97 | 28 |
| Januvia | Sitagliptin Phosphate | 96 | 11 |
| Alprazolam | Alprazolam | 95 | 32 |
| Levothyroxine Sodium | Levothyroxine Sodium | 94 | 28 |
| Restasis | Cyclosporine | 94 | 29 |
| Dutasteride | Dutasteride | 91 | 14 |
| Meclizine Hcl | Meclizine Hcl | 86 | 47 |
| Simvastatin | Simvastatin | 85 | 24 |
| Clobetasol Propionate | Clobetasol Propionate | 84 | 37 |
| Hydralazine Hcl | Hydralazine Hcl | 76 | 22 |
| Famotidine | Famotidine | 75 | 23 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 75 | 22 |
| Creon | Lipase/Protease/Amylase | 73 | 23 |
| Baclofen | Baclofen | 70 | 29 |
| Hydrochlorothiazide | Hydrochlorothiazide | 70 | 25 |
| Linzess | Linaclotide | 68 | 18 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 67 | 19 |
| Ketoconazole | Ketoconazole | 66 | 30 |
| Fenofibrate | Fenofibrate,micronized | 65 | 16 |
| Diclofenac Epolamine | Diclofenac Epolamine | 64 | 26 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 64 | 26 |
| Latanoprost | Latanoprost | 62 | suppressed |
| Carvedilol | Carvedilol | 58 | 17 |
| Telmisartan | Telmisartan | 58 | suppressed |
| Rivastigmine | Rivastigmine | 56 | 17 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 55 | 17 |
| Dexlansoprazole Dr | Dexlansoprazole | 54 | 16 |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 52 | suppressed |
| Nifedipine Er | Nifedipine | 52 | 13 |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 50 | 41 |
| Sildenafil Citrate | Sildenafil Citrate | 50 | suppressed |
| Nitroglycerin | Nitroglycerin | 49 | 30 |
| Prednisone | Prednisone | 49 | 27 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 47 | 35 |
| Metformin Hcl Er | Metformin Hcl | 46 | 15 |
| Ztlido | Lidocaine | 45 | 12 |
| Moxifloxacin | Moxifloxacin Hcl | 44 | 24 |
| Pioglitazone Hcl | Pioglitazone Hcl | 44 | suppressed |
| Ranolazine Er | Ranolazine | 44 | suppressed |
| Ciclopirox | Ciclopirox Olamine | 43 | 18 |
| Methimazole | Methimazole | 43 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 42 | 13 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 42 | 12 |
| Mirtazapine | Mirtazapine | 42 | suppressed |
| Clonidine | Clonidine | 40 | suppressed |
| Furosemide | Furosemide | 40 | 20 |
| Glipizide | Glipizide | 39 | suppressed |
| Levofloxacin | Levofloxacin | 38 | 29 |
| Ammonium Lactate | Ammonium Lactate | 37 | 21 |
| Fluoxetine Hcl | Fluoxetine Hcl | 37 | 13 |
| Propranolol Hcl | Propranolol Hcl | 37 | 11 |
| Rybelsus | Semaglutide | 37 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 36 | 17 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 36 | 11 |
| Eliquis | Apixaban | 35 | 13 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 35 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 35 | 30 |
| Sotalol | Sotalol Hcl | 35 | suppressed |
| Cephalexin | Cephalexin | 34 | 23 |
| Metoprolol Tartrate | Metoprolol Tartrate | 34 | suppressed |
| Procto-Med Hc | Hydrocortisone | 34 | 17 |
| Finasteride | Finasteride | 33 | suppressed |
| Fluocinonide | Fluocinonide | 33 | 15 |
| Tramadol Hcl | Tramadol Hcl | 33 | 15 |
| Xarelto | Rivaroxaban | 33 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 32 | 12 |
| Brilinta | Ticagrelor | 31 | suppressed |
| Ondansetron Odt | Ondansetron | 31 | 23 |
| Ursodiol | Ursodiol | 31 | suppressed |
| Evenity (2 Syringes) | Romosozumab-Aqqg | 30 | suppressed |
| Lansoprazole | Lansoprazole | 30 | suppressed |
| Ozempic | Semaglutide | 30 | suppressed |
| Valsartan | Valsartan | 30 | suppressed |
| Lactulose | Lactulose | 29 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 29 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 28 | 11 |
| Humalog Mix 50-50 Kwikpen | Insulin Lispro Protamin/Lispro | 28 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 27 | 12 |
| Hydrocortisone | Hydrocortisone | 27 | 14 |
| Colesevelam Hcl | Colesevelam Hcl | 26 | suppressed |
| Tenofovir Disoproxil Fumarate | Tenofovir Disoproxil Fumarate | 26 | suppressed |
| Lisinopril | Lisinopril | 25 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 25 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 25 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 24 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 24 | suppressed |
| Nystatin | Nystatin | 24 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 24 | 16 |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 24 | suppressed |
| Fluocinolone Acetonide | Fluocinolone Acetonide | 23 | suppressed |
| Myrbetriq | Mirabegron | 23 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 23 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 22 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 22 | suppressed |
| Colchicine | Colchicine | 22 | suppressed |
| Clonazepam | Clonazepam | 21 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 21 | 21 |
| Pregabalin | Pregabalin | 20 | suppressed |
| Zenpep | Lipase/Protease/Amylase | 20 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 19 | 12 |
| Mupirocin | Mupirocin | 19 | 11 |
| Vemlidy | Tenofovir Alafenamide | 19 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 18 | suppressed |
| Fenofibrate | Fenofibrate | 18 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 18 | suppressed |
| Repatha Sureclick | Evolocumab | 18 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 18 | suppressed |
| Gemfibrozil | Gemfibrozil | 17 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 17 | suppressed |
| Bepotastine Besilate | Bepotastine Besilate | 16 | suppressed |
| Betamethasone Diprop Augmented | Betamethasone/Propylene Glyc | 16 | 11 |
| Ciclopirox | Ciclopirox | 16 | suppressed |
| Estradiol | Estradiol | 16 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 16 | suppressed |
| Ofloxacin | Ofloxacin | 16 | 12 |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 15 | suppressed |
| Diflorasone Diacetate | Diflorasone Diacetate | 15 | suppressed |
| Dutasteride-Tamsulosin | Dutasteride/Tamsulosin Hcl | 15 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 15 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 15 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 15 | suppressed |
| Bethanechol Chloride | Bethanechol Chloride | 14 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 14 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 14 | suppressed |
| Repaglinide | Repaglinide | 14 | suppressed |
| Voquezna | Vonoprazan Fumarate | 14 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 13 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 13 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 13 | suppressed |
| Entresto | Sacubitril/Valsartan | 13 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 13 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 13 | suppressed |
| Advair Diskus | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 12 | suppressed |
| Febuxostat | Febuxostat | 12 | suppressed |
| Irbesartan | Irbesartan | 12 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Loperamide | Loperamide Hcl | 12 | suppressed |
| Omeprazole-Sodium Bicarbonate | Omeprazole/Sodium Bicarbonate | 12 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 11 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 11 | suppressed |
| Levetiracetam | Levetiracetam | 11 | suppressed |
| Lorazepam | Lorazepam | 11 | suppressed |
| Tradjenta | Linagliptin | 11 | suppressed |
| Ultra-Fine Micro Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $702.97 · 42 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, BREZTRI, CREON, EVENITY, FARXIGA, FREESTYLE LIBRE 3, JARDIANCE, Kerendia, LEQVIO, LINZESS, OTEZLA, REPATHA, VOQUEZNA | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Creon play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error